

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2024-25

Date: 13.02.2025

To

BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Code-531146

NSE Code: MEDICAMEQ

Sub. : Copy of Publication for Un-Audited Financial Results for the quarter and nine months ended on December 31, 2024

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 (“the Regulations”), please find enclosed newspaper cutting with regard to the publication of extract of Un-Audited Financial Results of the Company for the quarter and nine months ended on December 31, 2024 approved by the Board of Directors at their Meeting held on 11.02.2025.

The copy of the results published in the Financial Express and Jansatta dated 12.02.2025 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS-44157

Encl: As above.

MEDICAMEN BIOTECH LIMITED

Reg. Office: 1506, Chiranjiv Tower, 43, Nehru Place,
New Delhi, 110019 (India)

CIN: L74899DL1993PLC056594 Contact No.: 011-47589500

Website: www.medicamen.com Email: info@medicamen.com



**Statement of Unaudited Financial Results (Standalone and Consolidated)
for the quarter and nine months ended on December 31, 2024**

Based on the recommendation of Audit Committee, the Board of Directors of the Company, at their meeting held on February 11, 2025, approved the unaudited financial results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2024.

The financial results along with Limited Review Report have been posted on the website of the Company at www.medicamen.com and can be accessed by scanning the QR code given below:



For and on behalf of Board of Directors of
Medicamen Biotech Limited

Sd/-

Rahul Bishnoi

Director

DIN: 00317960

Place: New Delhi

Date: 11.02.2025

BERVIN INVESTMENT AND LEASING LIMITED

607, ROHIT HOUSE, 3, TOLSTOY MARG, NEW DELHI-110001

CIN : L65993DL1990PLC039397

Email Id:- secretary@bervin.com; Website: www.bervin.com

**STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND
NINE MONTHS ENDED DECEMBER 31, 2024**

The Board of Directors of Bervin Investment and Leasing Limited, at the meeting held on Monday, February 10, 2025, approved the Un-Audited Financial Results along with the Limited Review Report ("LRR") of the Company for the quarter and nine months ended December 31, 2024.

The results, along with Limited Review Report, have been posted on the Company's website at www.bervin.com and can be accessed by scanning the QR code.



By Order of the Board
For **BERVIN INVESTMENT AND LEASING LIMITED**

Sd/-

Satish Kumar Murgai

Director

Place: New Delhi

Date: 10.02.2025

Note:- The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

MUTHOOT FINCORP LTD. | सोने की नीलामी सूचना

Regd. Office: Muthoot Centre, TC No 27/3022, Punnén Road, Thiruvananthapuram, Kerala, India-695001.

CIN : U65929KL1997PLC011518, Ph: +91 471 4911400, 2331427

सभी सम्बद्ध व्यक्तियों की सूचना के लिए एतद्वारा सूचना दी जाती है कि 31.03.2024 & MSGL, SPL-16, One plus, Guide Prepaid, Super value, ADGL and all other 6 months tenure Gold loans up to 30.06.2024 and MSGB, SME Suvarna & EMI due up to 31.12.2024 तक की अवधि के लिए कम्पनी की नीचे कथित शाखाओं में गिरवी रखे सोने के गहनें जिन्हें छुड़ाने का समय बीत चुका है तथा जिन्हें बार-बार सूचना दिए जाने पर भी अब तक छुड़ाया नहीं गया है उनकी नीलामी 28.02.2025 को 10.00 बजे से शुरू कर दी जाएगी।

FARIDABAD SECT 15: 061500192, 061500218, 061500245, 061500259, 061500260, 061500267, 061500268, 061500269, 061500279, 061500280, 061500284, 061500297, 061500298, 061500307, 061500308, 061500309, 061500325, 061500337, F7788, GL/F15S/237, GL/F15S/45, GL/F15S/49, GL/F15S/97. FARIDABAD SECT 29: 0593000178, 0593000187, 0593000192, 0593000214, 0593000218, 0593000227, 0593000242, 0593000243, 0593000252, 0593000262, 0593000571, 0593000611, 0593000616, 0593000617, 0593000622, 0593000623, 0593000624, 0593000625, 0593000632, 0593000642, 0593000643, 0593000651

MEDICAMEN BIOTECH LIMITED

Reg. Office: 1506, Chiranjiv Tower, 43, Nehru Place,
New Delhi, 110019 (India)

CIN: L74899DL1993PLC056594 Contact No.: 011-47589500

Website: www.medicamen.com Email: info@medicamen.com



**Statement of Unaudited Financial Results (Standalone and Consolidated)
for the quarter and nine months ended on December 31, 2024**

Based on the recommendation of Audit Committee, the Board of Directors of the Company, at their meeting held on February 11, 2025, approved the unaudited financial results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2024.

The financial results along with Limited Review Report have been posted on the website of the Company at www.medicamen.com and can be accessed by scanning the QR code given below:



For and on behalf of Board of Directors of
Medicamen Biotech Limited

Sd/-

Rahul Bishnoi

Director

DIN: 00317960

Place: New Delhi

Date: 11.02.2025

Trejhara**Trejhara Solutions Limited**

CIN: L72900MH2017PLC292340

Regd. Office: Unit no. 601, Sigma IT Park, Plot no. R-203, R-204, T.T.C. Industrial Estate, Rabale, Navi. Mumbai - 400701.

Phone: +91-22-4040-8080 Fax: +91-22-4040-8081. Email: investor@trejhara.com; Website: www.trejhara.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended 31st December, 2024.

(₹ in lakhs)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from Operations	642.40	634.31	635.66	1,881.47	1,641.45	2,284.69
2	Net Profit for the period (before Tax, Exceptional items)	91.15	141.53	217.85	350.03	1,305.59	1,024.56
3	Net Profit for the period before tax (after Exceptional items)	91.15	141.53	198.45	350.03	1,162.43	2,257.94
4	Net Profit for the period after tax (after Exceptional items)	66.35	110.18	157.05	267.96	937.11	1,971.87
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	70.93	110.77	112.57	269.15	873.68	1,950.79
6	Equity Share Capital	1,451.63	1,451.63	1,451.63	1,451.63	1,451.63	1,451.63
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,669.13
8	Earnings per equity share (for Continuing and Discontinuing Operations)						
	- Basic (₹)	0.46	0.76	1.24	1.85	7.74	15.51
	- Diluted (₹)	0.46	0.76	1.24	1.85	7.74	15.51

Key numbers of Standalone Financial Results

₹ in lakhs

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Turnover	303.37	341.25	297.36	972.92	742.35	1,085.91
2	Profit/(Loss) before tax	68.35	71.37	55.52	193.29	(371.61)	755.38
3	Profit/(Loss) after tax	46.54	45.92	41.34	128.77	(618.23)	505.41

a) The above is an extract of the detailed format of Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended 31st December, 2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarter ended financial results are available on the websites of the Stock Exchange(s).